Effect of spectacle lenses designed to reduce relative peripheral hyperopia on myopia progression in Japanese children: a 2-year multicenter randomized controlled trial

Hiroyuki Kanda, Tetsuro Oshika, Takahiro Hiraoka, Satoshi Hasebe, Kyoko Ohno-Matsui, Satoshi Ishiko, Osamu Hieda, Hidemasa Torii, Saulius R. Varnas, Takashi Fujikado

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: Novel spectacle lenses (MyoVision, Carl Zeiss) designed to reduce relative peripheral hyperopia have been developed and reported to be effective for preventing myopia progression in a subgroup of Chinese children. In this study we examined the efficacy of MyoVision lenses in Japanese children. Study design: This was a multicenter prospective randomized double-blind placebo-controlled trial. Method: We enrolled 207 participants (aged 6–12 years) with spherical equivalent refractions (SERs) ranging from −1.5 to −4.5 diopters (D) and with at least 1 myopic parent. The participants were randomized to receive either single vision lenses (SVLs) or MyoVision lenses and were followed up every 6 months for 2 years. The primary outcome was myopia progression evaluated by cycloplegic autorefraction, and the secondary outcome was elongation of axial length. Results: A total of 203 children (98.1%) completed the follow-up. The mean adjusted change in SER was −1.43 ± 0.10 D in the MyoVision group, which was not significantly different from that of the control group wearing SVLs (−1.39 ± 0.07 D) at the 24-month visit (P =.65). The adjusted axial length elongation was 0.73 ± 0.04 mm in the MyoVision group, which was not significantly different from that in the control group wearing SVLs (0.69 ± 0.03 mm) at the 24-month visit (P =.28). Conclusion: The results of this clinical trial could not verify the therapeutic effect of MyoVision for slowing down myopia progression in Japanese children. Additional studies are needed to design lenses that can reduce peripheral hyperopic defocus individually and to examine the effectiveness of these lenses in preventing myopia progression.

Original languageEnglish
Pages (from-to)537-543
Number of pages7
JournalJapanese Journal of Ophthalmology
Volume62
Issue number5
DOIs
Publication statusPublished - 2018 Sep 1

Fingerprint

Hyperopia
Myopia
Lenses
Randomized Controlled Trials
Mydriatics
Control Groups
Therapeutic Uses
Placebos
Clinical Trials

Keywords

  • Myopia
  • Myopia progression control
  • Peripheral hyperopic defocus

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Effect of spectacle lenses designed to reduce relative peripheral hyperopia on myopia progression in Japanese children : a 2-year multicenter randomized controlled trial. / Kanda, Hiroyuki; Oshika, Tetsuro; Hiraoka, Takahiro; Hasebe, Satoshi; Ohno-Matsui, Kyoko; Ishiko, Satoshi; Hieda, Osamu; Torii, Hidemasa; Varnas, Saulius R.; Fujikado, Takashi.

In: Japanese Journal of Ophthalmology, Vol. 62, No. 5, 01.09.2018, p. 537-543.

Research output: Contribution to journalArticle

Kanda, Hiroyuki ; Oshika, Tetsuro ; Hiraoka, Takahiro ; Hasebe, Satoshi ; Ohno-Matsui, Kyoko ; Ishiko, Satoshi ; Hieda, Osamu ; Torii, Hidemasa ; Varnas, Saulius R. ; Fujikado, Takashi. / Effect of spectacle lenses designed to reduce relative peripheral hyperopia on myopia progression in Japanese children : a 2-year multicenter randomized controlled trial. In: Japanese Journal of Ophthalmology. 2018 ; Vol. 62, No. 5. pp. 537-543.
@article{dd2bb1873b8441a6a0dec98695c63f71,
title = "Effect of spectacle lenses designed to reduce relative peripheral hyperopia on myopia progression in Japanese children: a 2-year multicenter randomized controlled trial",
abstract = "Purpose: Novel spectacle lenses (MyoVision, Carl Zeiss) designed to reduce relative peripheral hyperopia have been developed and reported to be effective for preventing myopia progression in a subgroup of Chinese children. In this study we examined the efficacy of MyoVision lenses in Japanese children. Study design: This was a multicenter prospective randomized double-blind placebo-controlled trial. Method: We enrolled 207 participants (aged 6–12 years) with spherical equivalent refractions (SERs) ranging from −1.5 to −4.5 diopters (D) and with at least 1 myopic parent. The participants were randomized to receive either single vision lenses (SVLs) or MyoVision lenses and were followed up every 6 months for 2 years. The primary outcome was myopia progression evaluated by cycloplegic autorefraction, and the secondary outcome was elongation of axial length. Results: A total of 203 children (98.1{\%}) completed the follow-up. The mean adjusted change in SER was −1.43 ± 0.10 D in the MyoVision group, which was not significantly different from that of the control group wearing SVLs (−1.39 ± 0.07 D) at the 24-month visit (P =.65). The adjusted axial length elongation was 0.73 ± 0.04 mm in the MyoVision group, which was not significantly different from that in the control group wearing SVLs (0.69 ± 0.03 mm) at the 24-month visit (P =.28). Conclusion: The results of this clinical trial could not verify the therapeutic effect of MyoVision for slowing down myopia progression in Japanese children. Additional studies are needed to design lenses that can reduce peripheral hyperopic defocus individually and to examine the effectiveness of these lenses in preventing myopia progression.",
keywords = "Myopia, Myopia progression control, Peripheral hyperopic defocus",
author = "Hiroyuki Kanda and Tetsuro Oshika and Takahiro Hiraoka and Satoshi Hasebe and Kyoko Ohno-Matsui and Satoshi Ishiko and Osamu Hieda and Hidemasa Torii and Varnas, {Saulius R.} and Takashi Fujikado",
year = "2018",
month = "9",
day = "1",
doi = "10.1007/s10384-018-0616-3",
language = "English",
volume = "62",
pages = "537--543",
journal = "Japanese Journal of Ophthalmology",
issn = "0021-5155",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Effect of spectacle lenses designed to reduce relative peripheral hyperopia on myopia progression in Japanese children

T2 - a 2-year multicenter randomized controlled trial

AU - Kanda, Hiroyuki

AU - Oshika, Tetsuro

AU - Hiraoka, Takahiro

AU - Hasebe, Satoshi

AU - Ohno-Matsui, Kyoko

AU - Ishiko, Satoshi

AU - Hieda, Osamu

AU - Torii, Hidemasa

AU - Varnas, Saulius R.

AU - Fujikado, Takashi

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Purpose: Novel spectacle lenses (MyoVision, Carl Zeiss) designed to reduce relative peripheral hyperopia have been developed and reported to be effective for preventing myopia progression in a subgroup of Chinese children. In this study we examined the efficacy of MyoVision lenses in Japanese children. Study design: This was a multicenter prospective randomized double-blind placebo-controlled trial. Method: We enrolled 207 participants (aged 6–12 years) with spherical equivalent refractions (SERs) ranging from −1.5 to −4.5 diopters (D) and with at least 1 myopic parent. The participants were randomized to receive either single vision lenses (SVLs) or MyoVision lenses and were followed up every 6 months for 2 years. The primary outcome was myopia progression evaluated by cycloplegic autorefraction, and the secondary outcome was elongation of axial length. Results: A total of 203 children (98.1%) completed the follow-up. The mean adjusted change in SER was −1.43 ± 0.10 D in the MyoVision group, which was not significantly different from that of the control group wearing SVLs (−1.39 ± 0.07 D) at the 24-month visit (P =.65). The adjusted axial length elongation was 0.73 ± 0.04 mm in the MyoVision group, which was not significantly different from that in the control group wearing SVLs (0.69 ± 0.03 mm) at the 24-month visit (P =.28). Conclusion: The results of this clinical trial could not verify the therapeutic effect of MyoVision for slowing down myopia progression in Japanese children. Additional studies are needed to design lenses that can reduce peripheral hyperopic defocus individually and to examine the effectiveness of these lenses in preventing myopia progression.

AB - Purpose: Novel spectacle lenses (MyoVision, Carl Zeiss) designed to reduce relative peripheral hyperopia have been developed and reported to be effective for preventing myopia progression in a subgroup of Chinese children. In this study we examined the efficacy of MyoVision lenses in Japanese children. Study design: This was a multicenter prospective randomized double-blind placebo-controlled trial. Method: We enrolled 207 participants (aged 6–12 years) with spherical equivalent refractions (SERs) ranging from −1.5 to −4.5 diopters (D) and with at least 1 myopic parent. The participants were randomized to receive either single vision lenses (SVLs) or MyoVision lenses and were followed up every 6 months for 2 years. The primary outcome was myopia progression evaluated by cycloplegic autorefraction, and the secondary outcome was elongation of axial length. Results: A total of 203 children (98.1%) completed the follow-up. The mean adjusted change in SER was −1.43 ± 0.10 D in the MyoVision group, which was not significantly different from that of the control group wearing SVLs (−1.39 ± 0.07 D) at the 24-month visit (P =.65). The adjusted axial length elongation was 0.73 ± 0.04 mm in the MyoVision group, which was not significantly different from that in the control group wearing SVLs (0.69 ± 0.03 mm) at the 24-month visit (P =.28). Conclusion: The results of this clinical trial could not verify the therapeutic effect of MyoVision for slowing down myopia progression in Japanese children. Additional studies are needed to design lenses that can reduce peripheral hyperopic defocus individually and to examine the effectiveness of these lenses in preventing myopia progression.

KW - Myopia

KW - Myopia progression control

KW - Peripheral hyperopic defocus

UR - http://www.scopus.com/inward/record.url?scp=85052368138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052368138&partnerID=8YFLogxK

U2 - 10.1007/s10384-018-0616-3

DO - 10.1007/s10384-018-0616-3

M3 - Article

C2 - 30083910

AN - SCOPUS:85052368138

VL - 62

SP - 537

EP - 543

JO - Japanese Journal of Ophthalmology

JF - Japanese Journal of Ophthalmology

SN - 0021-5155

IS - 5

ER -